News Press Releases

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation of Claims Against Aduro BioTech, Inc. And Advises Investors With Losses To Contact The Firm

AAPL | May 16, 2016

Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Aduro BioTech, Inc. (“Aduro” or the “Company”) (Nasdaq: ADRO). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.

If you purchased or otherwise acquired Aduro shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on the Company’s May 16, 2016, announcement that its pancreatic cancer drug missed the primary endpoint in a Phase 2b clinical trial. Aduro's chairman, Stephen Isaacs, called the findings "unexpected" in light of "the divergence of these data from the results of our Phase 2a study."

If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.